medication regimens and sensor devices. Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related ...

Sales of the drug in the United States rose 19.1% ... Tzield, approved to delay the onset of type I diabetes, was added to Sanofi’s portfolio with the 2023 acquisition of Provention Bio.